Tags

Type your tag names separated by a space and hit enter

Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials.
J Clin Oncol. 2006 Oct 20; 24(30):4808-17.JC

Abstract

PURPOSE

A growing body of literature suggests that statins may have chemopreventive potential against cancer. Our aim was to examine the strength of this association through a detailed meta-analysis and meta-regression analysis of randomized controlled trials (RCTs).

METHODS

A comprehensive search for trials published up to 2005 was performed, reviews of each study were conducted, and data were abstracted. Before meta-analysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) estimates and 95% CIs were calculated using the random- and fixed-effects models. Subgroup, sensitivity, and meta-regression analyses were also conducted.

RESULTS

Thirty-five RCTs of statins for cardiovascular outcomes contributed to the analysis (n = 109,143). The degree of variability between trials was consistent with what would be expected to occur by chance alone. Statin use was not associated with a substantially increased or decreased overall risk of cancer (RR = 0.99; 95% CI, 0.94 to 1.04). Similarly, statin use did not significantly affect respiratory cancer risk (RR = 0.95; 95% CI, 0.83 to 1.09). However, the meta-regression analysis indicated that age of study participants modified the association between statin use and cancer risk (P = .003).

CONCLUSION

Our findings do not support a protective effect of statins against cancer. However, this conclusion is limited by the relatively short follow-up periods (4.5 years on average) of the studies analyzed. Thus, it is important to continue monitoring the long-term safety profiles of statins. Until then, physicians need to be vigilant in ensuring that statin use remains restricted to the approved indications.

Authors+Show Affiliations

Department of Pharmacology, School of Medicine, University of Athens, Greece. sbonovas@med.uoa.grNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis

Language

eng

PubMed ID

17001070

Citation

Bonovas, Stefanos, et al. "Statins and Cancer Risk: a Literature-based Meta-analysis and Meta-regression Analysis of 35 Randomized Controlled Trials." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 24, no. 30, 2006, pp. 4808-17.
Bonovas S, Filioussi K, Tsavaris N, et al. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol. 2006;24(30):4808-17.
Bonovas, S., Filioussi, K., Tsavaris, N., & Sitaras, N. M. (2006). Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 24(30), 4808-17.
Bonovas S, et al. Statins and Cancer Risk: a Literature-based Meta-analysis and Meta-regression Analysis of 35 Randomized Controlled Trials. J Clin Oncol. 2006 Oct 20;24(30):4808-17. PubMed PMID: 17001070.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. AU - Bonovas,Stefanos, AU - Filioussi,Kalitsa, AU - Tsavaris,Nikolaos, AU - Sitaras,Nikolaos M, Y1 - 2006/09/25/ PY - 2006/9/27/pubmed PY - 2006/11/7/medline PY - 2006/9/27/entrez SP - 4808 EP - 17 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J. Clin. Oncol. VL - 24 IS - 30 N2 - PURPOSE: A growing body of literature suggests that statins may have chemopreventive potential against cancer. Our aim was to examine the strength of this association through a detailed meta-analysis and meta-regression analysis of randomized controlled trials (RCTs). METHODS: A comprehensive search for trials published up to 2005 was performed, reviews of each study were conducted, and data were abstracted. Before meta-analysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) estimates and 95% CIs were calculated using the random- and fixed-effects models. Subgroup, sensitivity, and meta-regression analyses were also conducted. RESULTS: Thirty-five RCTs of statins for cardiovascular outcomes contributed to the analysis (n = 109,143). The degree of variability between trials was consistent with what would be expected to occur by chance alone. Statin use was not associated with a substantially increased or decreased overall risk of cancer (RR = 0.99; 95% CI, 0.94 to 1.04). Similarly, statin use did not significantly affect respiratory cancer risk (RR = 0.95; 95% CI, 0.83 to 1.09). However, the meta-regression analysis indicated that age of study participants modified the association between statin use and cancer risk (P = .003). CONCLUSION: Our findings do not support a protective effect of statins against cancer. However, this conclusion is limited by the relatively short follow-up periods (4.5 years on average) of the studies analyzed. Thus, it is important to continue monitoring the long-term safety profiles of statins. Until then, physicians need to be vigilant in ensuring that statin use remains restricted to the approved indications. SN - 1527-7755 UR - https://www.unboundmedicine.com/medline/citation/17001070/Statins_and_cancer_risk:_a_literature_based_meta_analysis_and_meta_regression_analysis_of_35_randomized_controlled_trials_ L2 - http://ascopubs.org/doi/full/10.1200/JCO.2006.06.3560?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -